EP0721940B1 - Verfahren zur Herstellung von Ajoen - Google Patents
Verfahren zur Herstellung von Ajoen Download PDFInfo
- Publication number
- EP0721940B1 EP0721940B1 EP96100318A EP96100318A EP0721940B1 EP 0721940 B1 EP0721940 B1 EP 0721940B1 EP 96100318 A EP96100318 A EP 96100318A EP 96100318 A EP96100318 A EP 96100318A EP 0721940 B1 EP0721940 B1 EP 0721940B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- allicin
- cyclodextrin
- ajoen
- water
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Definitions
- the invention relates to a method for producing Ajoen using cyclodextrin.
- Garlic has been an important spice and for thousands of years Food is also one of the best known and most versatile Remedies in folk medicine of many peoples. Especially but it is still common today - lately more and more - as an effective remedy for a variety of diseases taken such as for various infectious diseases, with some metabolic disorders and in particular for cardiovascular diseases. Its healing effects have also been intense by the in recent decades driven pharmacological research confirmed.
- DE-C-29 48 869 (corresponds to GB 2061987) an attempt was therefore made Allicin with exclusion of oxygen with cyclodextrins to complex to thereby include cyclodextrin inclusion complexes and get allicin that are more stable than that Allicin itself. Furthermore, DE-C-29 48 869 describes the use the cyclodextrin / allicin complexes as medicinal products described. As can be seen from the examples of the application, the stability of the complexes is higher than that Stability of allicin, but still too low for that they are suitable as long-term stable pharmaceutical preparations would be. In addition, for pharmaceutical applications, Active substances not in complex form are desirable.
- Ajoen is very stable and therefore for standardisable Suitable preparations, but its extraction is a problem because it from Allicin only under time or costly conditions can be obtained in low yields.
- the object of the present invention was to achieve an economical Processes for obtaining ajoes are available too provide, which avoids the disadvantages of the prior art.
- the problem is solved by a method which thereby is characterized in that allicin in water and / or dissolved in a water-miscible solvent, with ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin or any Mixture of these cyclodextrins combined and processed into a water-containing composition, this composition is dried and the resulting Ajoen by decomplexing and extracting from the dried Composition is obtained.
- the dried Product before decomplexing with an anhydrous organic Treated solvent Increased by this step the yield of ajoen significantly.
- the method according to the invention makes it possible to pharmacologically highly effective substance Ajoen available in quantities to provide the production of an ajoene-containing standardizable Remedy possible.
- allicin is not commercially available due to its instability it is preferably isolated from either garlic or by known methods, for example by Oxidation of the commercially available diallyl disulfide produced (Cavallito, C.J., Bailey, J.H., J. Am. Chem. Soc. 66, (1944), 1950-1951; Small, L.V.D., Bailey, J.H. Cavallito C. J., J. Am. Chem. Soc. 69, (1947), 1710 - 1713).
- Suitable solvents for allicin are water and / or all water-miscible solvents, the use of which does not additionally jeopardize the low stability of allicin.
- examples of such solvents are lower (C 1 to C 4 ) alkanols or ketones.
- Water, ethanol or an ethanol / water mixture in a ratio of 1: 1 to 1:99 is preferably used as the solvent. Since the concentration of allicin in the solvent also has a strong influence on the stability of allicin, preference is given to working with highly dilute allicin solutions.
- Allicin is particularly advantageous in the process according to the invention therefore as about 1% aqueous or aqueous / alcoholic solution used.
- allicin is preferred at low temperatures about -30 ° C or lower long-term storage.
- ⁇ -Cyclodextrin and / or ⁇ -cyclodextrin are preferably suitable used.
- the cyclodextrins can be used as an aqueous solution, as a concentrated one Suspension or paste or used in powder form become.
- aqueous solution they are preferably saturated Solution used.
- Cyclodextrin and allicin are preferably in a molar ratio from 1: 2 to 1: 0.5, particularly preferably 1: 1.2 to 1: 0.8 mixed.
- Mixing the cyclodextrin or the cyclodextrin solution or suspension or paste with the allicin solution is at 2-70 ° C, preferably at initial temperatures of 30-50 ° C and slow cooling to 2 to about 20 ° C in usually carried out, for example, by stirring.
- the mixing is preferably carried out over a period of 1 up to 48 h, particularly preferably 2 to 4 h.
- the mixing process can be done under normal conditions (air) or with exclusion of oxygen in the presence of an inert gas, for example Nitrogen. He usually is under normal conditions, i.e. in present carried out by air.
- the homogeneous mixture obtained is as such after a any method commonly used in practice.
- the mixture turns on at room temperature in air or under vacuum at 20 to 120 ° C, preferably at 30 up to 90 ° C or by freeze drying or by spray drying dried.
- Suitable solvents in this regard are preferred anhydrous ethers, lower alkanols, ketones or chlorinated hydrocarbons.
- Anhydrous is particularly suitable Diethyl ether.
- the dry product with the solvent all at once or in 2 to 3 subsets 1:60 to 1: 3 for a total period of 60 to 300 preferably 90 to 180 min at room temperature (approx. 20 ° C) or mixed by boiling under reflux conditions and then after removal of the solvent (e.g. in a rotary evaporator dried under vacuum) in a manner known per se. Drying can be done in a vacuum drying cabinet, for example at 30 to 120 ° C.
- the complex formed in 2 isomeric forms (cis, trans) Ajoen is made from the dry product by conventional decomplexing methods extracted and for example with the help of a suitable solvent isolated.
- All decomplexation methods are based on solving or Suspend the complexes in plenty of water and extract the enclosed guest substance from the aqueous phase using a non-polar solvent and recovery from the extract.
- the extraction of the ajoen from the ajoene / cyclodextrin complex thus takes place according to the invention by decomplexing with mixtures from water and at least one non-polar organic Solvent, the separation of the organic and the aqueous phase, and the extraction of the ajoene from the organic Phase, for example by means of drying.
- Suitable organic solvents for Ajoen are all known Solvents for ajoens such as ethers or chlorinated hydrocarbons. Diethyl ether is particularly suitable and petroleum ether.
- the resultant is obtained dried organic phase using known methods.
- the ajoen can then, if desired, by known Processes such as further purified by preparative HPLC become.
- the degree of conversion of allicin to ajoene in the presence of Cyclodextrins is dependent on both the one used Cyclodextrin as well as the complexing and post-treatment conditions. It is among the preferred ones mentioned Conditions and especially when treating the cyclodextrin complex with an anhydrous organic solvent, preferably an ether, highest.
- the in the inventive method by converting the Allicin's formed ajoens can be both complex and Cyclodextrin / Ajoen complex used in pure form as well become.
- the cyclodextrin / ajoene complexes or the ajoene produced according to the invention mainly comes the pharmaceutical sector in question. There it can be seen as stable and therefore standardizable preparation especially against cardiovascular complaints such as. Arteriosclerosis, signs of thrombosis, high blood pressure etc. as well as against various bacterial infections and as a cure for some Use organ and metabolic disorders.
- the allicin used in the examples was according to the Cavallito (Cavallito, C.J., Bailey, J.H., J. Am. Chem. Soc. 66, (1944), 1950 - 1951) described method from fresh Garlic isolated.
- This intermediate was dissolved in 3000 ml of water for 5 hours with vigorous stirring. The slightly cloudy solution was then extracted three times with 500 ml of diethyl ether each time. The combined ether extract was dehydrated by freezing (CO 2 / acetone bath) and then concentrated in a rotary evaporator under vacuum to remove the ether.
- the residue of 0.45 g obtained in this way contains, according to 1 H-NMR analysis, 30.5% ajoen based on the allicin used (approx. 0.156 g) (10.3% shares in cis-ajoen, 20, 2% shares of trans-Ajoen).
- the ajoene was obtained from the complex by solving the product thus obtained in 3000 ml of water (5 hours intensive Stirring) and subsequent extraction etc. as in example 1 described.
- the residue of the ether extracts collected was 0.42 g.
- the Ajoen yield was 49.5% based on the one used Allicin (approx. 0.34 g). It consisted of 37.1% cis and 12.4% trans ajoen.
- the extraction residue of 0.8 g contained 37.4% ajoene, consisting of 14.2% cis-Ajoen and 23.2% trans-Ajoen on the amount of allicin used.
- Decomplexing was carried out as follows: the freeze-dried one Powder (9.5 g) was washed with 600 ml of water had been slightly acidified with HCl (pH 2-3), 1.5 hours below Reflux cooked. The solution obtained was three times with each Shaken out 200 ml ether. The combined ether extract was dehydrated by freezing and concentrated in vacuo.
- the freeze-dried powder was three times each with 30 min 150 ml of diethyl ether shaken and then in a vacuum drying cabinet dried.
- Example 2 The ajoene was then made from this dry powder as in Example 1 described extracted by decomplexing. in the extraction residue of 0.9 g obtained was 0.457 g Ajoen determined. This corresponds to an Ajoen yield of 45.7%.
- a culture medium solution (LB medium) were first poured out onto a sterile petri dish with a diameter of 10 cm. After the approx. 1 cm thick layer had solidified, an approx. 1 mm thick bacterial culture (Bacillus subtilis) was layered over it (solution a + b) and then a filter plate (approx. 10 mm diameter) soaked with 40 ⁇ l of the substance to be examined ) with sterile forceps. The solution was allowed to act on the bacterial layer in the refrigerator (5 ° C.) for about 2 hours and then incubated at 28 ° C. for about 16 hours. The zone of inhibition formed around the filter plate was measured (diameter or width) and photographed.
- LB medium culture medium solution
- Solution a nutrient solution (LB liquid) 10 g trypton 5 g yeast extract 5 g NaCl were made up with water and sterilized 1 l
- Solution b LB soft agar 5 g tryptone 2.5 g yeast extract 2.5 g NaCl 3.0 g agar were made up with water and sterilized 1 l
- the filter paper plates were also 20 minutes at 120 ° C. sterilized.
- Bacillus subtilis culture solution 1 ml of Bacillus subtilis culture solution is placed in an Erlenmeyer flask pipetted with 10 ml nutrient solution (solution a) and culture overnight at 37 ° C and 260 rpm in a water bath vibrator grown.
- the inhibition yard images shown in Fig. 1 show that at Active substance concentrations equal to 800 ⁇ g / ml with Ajoen good antibacterial inhibitory effects can be achieved as with Allicin, while when using diallyl disulfide, the Main component of "garlic oil", no effect at all is achieved.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
- 1 = Allicin
- Konzentration: 800 µg/ml
- 2 = Diallyldisulfid
- Konzentration: 800 µg/ml
- 3 = Ajoen
- Konzentration: 800 µg/ml
Lösung a = Nährlösung (LB-flüssig) | |
10 g Trypton | |
5 g Hefeextrakt | |
5 g NaCl | wurden mit Wasser auf aufgefüllt und sterilisiert |
1 l | |
Lösung b = LB-Weichagar | |
5 g Trypton | |
2,5 g Hefeextrakt | |
2,5 g NaCl | |
3,0 g Agar | wurden mit Wasser auf aufgefüllt und sterilisiert |
1 l |
Claims (7)
- Verfahren zur Gewinnung von Ajoen, dadurch gekennzeichnet, daß Allicin ggf. in Wasser und/oder einem mit Wasser mischbaren Lösungsmittel gelöst, mit α-Cyclodextrin, β-Cyclodextrin, γ-Cyclodextrin oder einer beliebigen Mischung dieser Cyclodextrine zusammengegeben und zu einer wasserhaltigen Zusammensetzung verarbeitet wird, diese Zusammensetzung getrocknet wird und das entstandene Ajoen durch Dekomplexieren und Extraktion aus der getrockneten Zusammensetzung erhalten wird.
- Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß die getrocknete Zusammensetzung vor dem Dekomplexieren mit einem wasserfreien organischen Lösungsmittel behandelt wird.
- Verfahren gemäß Anspruch 2, dadurch gekennzeichnet, daß als wasserfreies organisches Lösungsmittel Ether eingesetzt wird.
- Verfahren gemäß Anspruch 3, dadurch gekennzeichnet, daß als Ether Diethylether eingesetzt wird.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß das Allicin in Form einer etwa 1% igen wäβrigen Lösung eingesetzt wird.
- Verfahren gemäß einem oder mehreren der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß als Cyclodextrin β-Cyclodextrin und/oder γ-Cyclodextrin eingesetzt wird.
- Komplexe von α-, β- oder γ-cyclodextrin mit Ajoen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19500863 | 1995-01-13 | ||
DE19500863A DE19500863A1 (de) | 1995-01-13 | 1995-01-13 | Verfahren zur Herstellung von Ajoen |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0721940A1 EP0721940A1 (de) | 1996-07-17 |
EP0721940B1 true EP0721940B1 (de) | 1999-12-22 |
Family
ID=7751433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96100318A Expired - Lifetime EP0721940B1 (de) | 1995-01-13 | 1996-01-11 | Verfahren zur Herstellung von Ajoen |
Country Status (4)
Country | Link |
---|---|
US (1) | US5741932A (de) |
EP (1) | EP0721940B1 (de) |
JP (1) | JP2820653B2 (de) |
DE (2) | DE19500863A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377219A (en) * | 2001-07-04 | 2003-01-08 | Neem Biotech Ltd | Preparation of allicin |
CN1324142C (zh) * | 2003-03-18 | 2007-07-04 | 陆茂松 | 一种含有阿霍烯的脱脂大蒜提取物及其制备方法和应用 |
US20090092619A1 (en) * | 2004-08-11 | 2009-04-09 | Photini Sinnis | Methods and compositions for malaria prophylaxis |
US20060122266A1 (en) * | 2004-08-11 | 2006-06-08 | Photini Sinnis | Methods and compositions for malaria prophylaxis |
KR100691805B1 (ko) * | 2005-08-03 | 2007-03-12 | 삼성전자주식회사 | 어호엔을 알코올 분해 효소 저해제로 사용하는 방법, 상기 어호엔을 포함하는 숙취 제거 조성물 및 상기 숙취 제거 조성물의 제조 방법 |
US8555544B2 (en) * | 2006-02-10 | 2013-10-15 | Profile Products L.L.C. | Visual attenuation compositions and methods of using the same |
US8256158B2 (en) * | 2007-01-04 | 2012-09-04 | Profile Products Llc | Visual attenuation compositions and methods of using the same |
GB0903869D0 (en) | 2009-03-05 | 2009-04-22 | Neem Biotech Ltd | Process for the preparation of ajoene |
GB201420902D0 (en) | 2014-11-25 | 2015-01-07 | Neem Biotech Ltd | A process for producing Ajoene |
CN105395572B (zh) * | 2015-12-25 | 2020-01-21 | 成都市新功生物科技有限公司 | 豚鼠人工熊胆粉的制备方法 |
CN105535024B (zh) * | 2015-12-25 | 2020-01-21 | 成都市新功生物科技有限公司 | 一种豚鼠人工熊胆粉的制备方法 |
CN107789345B (zh) * | 2016-09-07 | 2022-06-28 | 汤臣倍健股份有限公司 | 矫味大蒜素-环糊精复合物及其制备方法 |
CN107802842B (zh) * | 2016-09-07 | 2022-04-12 | 汤臣倍健股份有限公司 | 大蒜素矫味制剂及其制备方法 |
CN106957883A (zh) * | 2017-04-06 | 2017-07-18 | 山东晨隆晟世生物科技有限公司 | 一种大蒜素合成阿霍烯的工艺方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU177081B (en) * | 1978-12-12 | 1981-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing the occlusion complex of allicin with cyclodextrin |
US4665088A (en) * | 1984-11-14 | 1987-05-12 | The Research Foundation Of State University Of New York | (E-Z)-4,5,9-trithiadodeca-1,6,11-triene 9-oxides |
US4643994A (en) * | 1984-12-17 | 1987-02-17 | The Research Foundation Of State University Of New York | Novel organic trithio oxides and method for the preparation thereof |
-
1995
- 1995-01-13 DE DE19500863A patent/DE19500863A1/de not_active Withdrawn
- 1995-11-13 US US08/555,981 patent/US5741932A/en not_active Expired - Fee Related
-
1996
- 1996-01-11 EP EP96100318A patent/EP0721940B1/de not_active Expired - Lifetime
- 1996-01-11 DE DE59603938T patent/DE59603938D1/de not_active Expired - Fee Related
- 1996-01-12 JP JP8020645A patent/JP2820653B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE59603938D1 (de) | 2000-01-27 |
JP2820653B2 (ja) | 1998-11-05 |
US5741932A (en) | 1998-04-21 |
DE19500863A1 (de) | 1996-07-18 |
JPH08259525A (ja) | 1996-10-08 |
EP0721940A1 (de) | 1996-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0721940B1 (de) | Verfahren zur Herstellung von Ajoen | |
DE2524355C2 (de) | Tetrahydropyranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE2948869C2 (de) | ||
DE2329486A1 (de) | Neue antibiotika und verfahren zu ihrer herstellung | |
DE3940091A1 (de) | Extrakt aus blaettern von ginkgo biloba, verfahren zu seiner herstellung und den extrakt enthaltende arzneimittel | |
Weidel et al. | Die gemeinsame Wurzel der Lyse von Escherichia coli durch Penicillin oder durch Phagen: (Zugleich II. Mitt. über „Phagenenzym") | |
EP0692257A1 (de) | Verfahren zur Herstellung von pestizidarmen Wirkstoffkonzentraten aus Pflanzen | |
DE19756848C2 (de) | Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen | |
WO2015117793A1 (de) | Verbessertes verfahren zur herstellung von ginkgoextrakten | |
CH647534A5 (de) | Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate. | |
DE4202657A1 (de) | Verfahren zur extraktion von pharmazeutisch wirksamen zusammensetzungen, pharmazeutisch wirksame zusammensetzung und damit hergestelltes arzneimittel | |
CH644845A5 (de) | N-(4-acyloxyphenyl)-all-trans-retinsaeureamide. | |
DE2462691C2 (de) | ||
EP0220453B1 (de) | Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung | |
DE2850509C3 (de) | O-Methoxyzimtaldehyd bei der Bekämpfung von Dermatophyten | |
DE19800330C2 (de) | Pharmazeutisch wirksamer CO¶2¶-Extrakt aus Tanacetum parthenium | |
DE3417576A1 (de) | Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung | |
EP0508330B1 (de) | Verfahren zur Herstellung von Extrakten aus Rhizoma Petasitidis mit Kohlendioxid | |
EP3290044A1 (de) | Antibakterielle zusammensetzung, umfassend einen pflanzenextrakt, verfahren zur gewinnung des extrakts, pharmazeutische zusammensetzung und deren verwendung | |
CH642039A5 (de) | Verfahren zur gewinnung natuerlicher terpene mit antipsoriatischer wirksamkeit und gemaess diesem verfahren hergestellte terpene. | |
WO1988000579A1 (en) | Means and process for improving and keeping soils and vegetable growth naturally healthy | |
DE2759032C2 (de) | ||
EP1116715B1 (de) | Tetramsäure-Derivate zur Verwendung in Medizin und Lebensmitteltechnologie | |
DE2358434A1 (de) | Verfahren zur reinigung von pflanzlichen flavonextrakten | |
DE2246205A1 (de) | Verfahren zur gewinnung eines extrakts aus arnica montana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE FR GB IT |
|
17Q | First examination report despatched |
Effective date: 19980123 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR GB IT |
|
REF | Corresponds to: |
Ref document number: 59603938 Country of ref document: DE Date of ref document: 20000127 |
|
ITF | It: translation for a ep patent filed |
Owner name: JACOBACCI & PERANI S.P.A. |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20000224 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20021218 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20030108 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20030131 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040803 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20040111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040930 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050111 |